We found eight EGFR activating point mutations (22.2%, n = 36) in 5/29 patients (17.2%): six of these were considered rare variants (p.V774M, p.T751I and p.S752Y in exon 19; p.G719S and p.A702D in exon 18; p.E66K in exon 21) that are usually described in non-small cell lung cancer. Here, EGFR is linked to non-small cell lung carcinoma.